Buy & Sell iShares MSCI China ETF (MCHI) – iShares MSCI China ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Broad Market / FactorSector
- -8.95%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 23 daysTypical Hold Time
Over the past 52 weeks, iShares MSCI China ETF has traded between a low of $53.5 and a high of $66.99, highlighting its annual price range. Over the past three months, iShares MSCI China ETF has recorded a drawdown of -8.95%, reflecting recent price volatility. On average, investors hold iShares MSCI China ETF for approximately 23 days, indicating typical investor behavior on the platform.
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Most Recent News
Cyabra inks $500K+ deal to fight online hate with AI-powered disinformation detection for global research institute
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...

Ormat launches Ormega100, the largest binary geothermal unit, to boost Enhanced Geothermal System deployment.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...

ADARx to present Phase 1/2 data on Onvuzosiran for hereditary angioedema at 2026 EAACI Congress
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
